Syndros Approval History
- FDA approved: Yes (First approved July 1st, 2016)
- Brand name: Syndros
- Generic name: dronabinol
- Dosage form: Oral Solution
- Company: Insys Therapeutics, Inc.
- Treatment for: Anorexia, Nausea/Vomiting, Chemotherapy Induced
Syndros (dronabinol) is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol (THC) approved for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
Development History and FDA Approval Process for Syndros
|Jul 5, 2016||Insys Therapeutics Announces FDA Approval of Syndros (dronabinol) Oral Solution|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.